丽珠医药(01513.HK)附属出资4,900万人币与关连方设立药品生产合营
丽珠医药(01513.HK)公布,公司控股附属新北江制药与焦作健康元订立共同投资协议,双方同意共同以现金方式投资设立合资公司河南研究院,其中新北江制药出资4,900万元人民币(下同),占比49%,焦作健康元出资5,100万元,占比51%。
河南研究院的经营范围为包括药品的生产、兽药的生产、医药中间体的制造、化工原料及产品的制造等。
健康元直接及间接持有公司已发行股本总额约44.35%股权,而焦作健康元由健康元直接及间接持有100%权益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.